Treatment of lipids and type 2 diabetes
- PMID: 15485606
- DOI: 10.1007/s11886-004-0053-4
Treatment of lipids and type 2 diabetes
Abstract
The development of type 2 diabetes is increasing in epidemic proportions. There is a significant risk for cardiovascular disease, which is the most prevalent and detrimental complication for the diabetic population. Serum lipid abnormalities are common in patients with diabetes, and due to this increased vascular risk, it is recommended to aggressively treat the hyperlipidemia. Therefore, intensive lipid-lowering therapy should be used for primary and secondary prevention against macrovascular complications for patients with type 2 diabetes. In this article some of the key studies justifying the need for lipid reduction in patients with type 2 diabetes are reviewed and practical guidelines for management of the dyslipidemia are suggested.
Similar articles
-
Management of Lipids in Patients with Diabetes.Nurs Clin North Am. 2017 Dec;52(4):605-619. doi: 10.1016/j.cnur.2017.07.009. Nurs Clin North Am. 2017. PMID: 29080581 Review.
-
Lipid-lowering therapy in diabetes mellitus.Neth J Med. 2001 May;58(5):214-22. doi: 10.1016/s0300-2977(01)00105-x. Neth J Med. 2001. PMID: 11414234 Review.
-
Treating lipid abnormalities in patients with type 2 diabetes mellitus.Am J Cardiol. 2001 Dec 20;88(12A):37N-40N. doi: 10.1016/s0002-9149(01)02151-8. Am J Cardiol. 2001. PMID: 11788129 Review.
-
[Statins (HMG-CoA reductase inhibitors)].Nihon Rinsho. 2006 Nov;64(11):2113-8. Nihon Rinsho. 2006. PMID: 17087305 Review. Japanese.
-
[Lipids: diagnosis and therapy in type 2 diabetes].Wien Klin Wochenschr. 2012 Dec;124 Suppl 2:28-30. doi: 10.1007/s00508-012-0273-3. Wien Klin Wochenschr. 2012. PMID: 23250461 German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical